Aurora Cannabis Delivers $8 Million Shipment of Cannabis to Israel

Rhea-AI Summary

Aurora Cannabis (ACB) announced a significant cannabis shipment worth nearly C$8 million to Israel, marking one of the largest single cannabis shipments received by the country. This delivery aligns with Aurora's strategy to enhance its international medical cannabis business, focusing on key markets like Israel, where THC recreational markets are on the horizon. The company has a supply agreement with Cantek Global Ltd. to provide a minimum of 4,000 kg of bulk dried flower annually, showcasing Aurora's commitment to expanding its medical cannabis portfolio globally.

Positive

• C$8 million cannabis shipment to Israel enhances international market presence.
• Minimum supply agreement of 4,000 kg of cannabis annually demonstrates strong market commitment.
• Positioned for growth in the emerging Israeli THC and CBD markets.

Negative

• None.

Shipment is part of the Company's strategy to advance its leadership in the global cannabinoid space

NASDAQ | TSX: ACB

EDMONTON, AB, July 15, 2021 /PRNewswire/ - Aurora Cannabis Inc. (the "Company" or "Aurora") (NASDAQ: ACB) (TSX: ACB), the Canadian company defining the future of cannabinoids worldwide, announced today the delivery of a cannabis shipment worth nearly C$8 million, in one of the largest single shipments of cannabis that Israel has received.

The sale is a significant step in advancing the Company's international medical business, a key strategic priority for Aurora as a global cannabis company. With leadership in both Canada and Europe, Aurora is uniquely positioned to be a partner of choice in countries like Israel, where THC recreational markets are expected to be around the corner, and non-THC cannabinoids, such as CBD, are advancing toward legalization.

"We are excited about the evolution of the cannabis industry in Israel and commend the Ministry of Health and the Israeli Medical Cannabis Agency for ensuring thoughtful regulation of cannabis, in the best interest of Israeli cannabis patients," says Miguel Martin, Chief Executive Officer of Aurora. "We look forward to continuing to provide high-quality cannabis to Israel, as part of our strategy to expand our medical cannabis portfolio in key international markets."

The Company, which has a strategic supply agreement with Cantek Global Ltd., one of Israel's leaders in the medical cannabis field, intends to supply a minimum of 4,000 kg of bulk dried flower annually to Israel.

About Aurora

Aurora is a global leader in the cannabis industry serving both the medical and consumer markets. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis dedicated to helping people improve their lives. The Company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler, and Reliva CBD. Driven by science and innovation and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched. For more information, please visit our website at www.auroramj.com. 

Aurora's common shares trade on the TSX and NASDAQ under the symbol "ACB" and is a constituent of the S&P/TSX Composite Index. 

Forward Looking Statements

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include statements regarding  the Company's continued supply of cannabis to Israel and the amount of cannabis to be supplied to Israel. These forward-looking statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward looking statements are based on the opinions, estimates and assumptions of management in light of management's experience and perception of historical trends, current conditions and expected developments at the date the statements are made, such as current and future market conditions, the ability to maintain SG&A costs in line with current expectations, the ability to achieve high margin revenues in the Canadian consumer market, the current and future regulatory environment and future approvals and permits. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements, including the risks associated with: entering the U.S. market, the ability to realize the anticipated benefits associated with the acquisition of Reliva, achievement of Aurora's business transformation plan, general business and economic conditions, changes in laws and regulations, product demand, changes in prices of required commodities, competition, the effects of and responses to the COVID-19 pandemic and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information form dated September 24, 2020 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR at www.sedar.com and filed with and available on the SEC's website at www.edgar.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. 

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-cannabis-delivers-8-million-shipment-of-cannabis-to-israel-301334295.html

SOURCE Aurora Cannabis Inc.

FAQ

What was the value of Aurora Cannabis's shipment to Israel?

Aurora Cannabis delivered a shipment worth nearly C$8 million to Israel.

How much cannabis is Aurora Cannabis committed to supplying to Israel annually?

Aurora Cannabis intends to supply a minimum of 4,000 kg of bulk dried flower annually to Israel.

What is Aurora Cannabis's focus regarding international markets?

Aurora Cannabis is focusing on expanding its international medical cannabis business, particularly in markets like Israel.